Invaio Sciences focuses on unlocking the potential of natural systems to accelerate the transition to sustainable agriculture and address climate change. The company develops platforms that draw on discoveries from human therapeutics, agriculture, environmental science, and advanced manufacturing. Founded by Flagship Pioneering in 2018, Invaio is based in Cambridge, Massachusetts and is led by CEO Ignacio Martinez. Its stated near-term plans include accelerating research, development and commercialization of its platforms. The company has secured external financing to support those plans. Recent financing activity reflects a focus on funding R&D and commercialization rather than operating-metrics-driven expansion. Invaio Sciences develops multi-platform biological and systems-based solutions to address agricultural, nutritional and environmental challenges. The company leverages the planet’s interdependent natural systems and focuses R&D on perennial, row crop and vegetable marketplaces. Its discovery areas include tree nutritional health, insect management, vector and disease control, replacements for herbicides and fungicides, advanced seed technologies and carbon cycling. Invaio plans to use the new funding to roll out solutions for specific problems such as HLB in citrus, Xylella in olive production, and to refine practices for vineyards and orchards. The company is led by Ignacio Martinez (CEO), Gerardo Ramos (Chief Science Officer) and Peleg Chevion (President and Chief Commercial Officer). Financially, Invaio closed an $88.9M Series C and has raised more than $142M since its founding in 2018.

Total raised

$139M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Oct 2021